3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Breast Cancer -

Drop in breast cancer tied to less HRT

Breast CancerDec 16, 06

A sharp decline in new breast cancer cases in 2003 in the United States may have come about because millions of older women ceased hormone replacement therapy (HRT) the previous year, researchers said on Thursday.

However, they stressed that because their analysis is based on population statistics, the reasons are not completely certain.

“The investigators report that there was an overall 7 percent relative decline in breast cancer incidence between 2002 and 2003,” the University of Texas M. D. Anderson Cancer Center said in a statement.

“The steepest decline—12 percent—occurred in women between ages 50-69 diagnosed with estrogen receptor positive (ER-positive) breast cancer,” it said. These types of tumors are fueled by the hormone estrogen.

The study was presented at the 29th annual San Antonio Breast Cancer Symposium.

Researchers said that as many as 14,000 fewer women were diagnosed with the disease in 2003 than in 2002, a year in which there were an estimated 203,500 new U.S. cases.

“It is the largest single drop in breast cancer incidence within a single year I am aware of,” said Dr. Peter Ravdin, a research professor in the Department of Biostatistics at M. D. Anderson.

“Something went right in 2003, and it seems that it was the decrease in the use of hormone therapy, but from the data we used we can only indirectly infer that is the case,” he said in a statement.

HRT provides the hormone estrogen and sometimes also progestin to women after menopause. A big study, the Women’s Health Initiative, in 2002 suggested that the combination of estrogen and progestin raised the risk of breast cancer. This brought a premature halt to the study of more than 16,600 women between 50 and 79 who were using HRT, and caused widespread confusion

More analysis of the Women’s Health Initiative also showed that HRT could raise the risk of heart disease and especially strokes, and HRT was abandoned except as a way to relieve the most debilitating and stressful symptoms of menopause, such as hot flashes and insomnia.

Ravdin said about 30 percent of American women over the age of 50 had been taking HRT in the early years of this decade but about half of the women stopped in the later part of 2002 after the results of this link were made public.

“Research has shown that ER-positive tumors will stop growing if they are deprived of the hormones, so it is possible that a significant decrease in breast cancer can be seen if so many women stopped using HRT,” he said.

“It takes breast cancer a long time to develop, but here we are primarily talking about existing cancers that are fueled by hormones and that slow or stop their growing when a source of fuel is cut,” added Donald Berry, an M.D. Anderson professor who helped lead the study.

“Incidence of breast cancer had been increasing in the 20 or so years prior to July 2002, and this increase was over and above the known role of screening mammography. HRT had been proposed as a possible factor, although the magnitude of any HRT effect was not known.”



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  Fat grafting technique improves results of breast augmentation
  UW research shows sensor technology may help improve accuracy of clinical breast exams
  Generic Breast Cancer Drugs Boost Adherence
  New models of drug-resistant breast cancer point to better treatments
  Breast tomosynthesis increases cancer detection and reduces recall rates
  2 views are better than 1 in 3-D breast screening
  Study reveals genomic similarities between breast cancer and ovarian cancers
  Moderate exercise tied to lower breast cancer risk
  Risk for some cancers rises with U.S. obesity rate
  New genomic test spares patients chemotherapy with no adverse effect on survival
  Breast Cancer In Black Women Is A Different Disease
  Combination of Everolimus and Exemestane Improves Progression-Free Survival for Women with Metastatic Breast Cancer

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site